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Abstract
Introduction: Recently published large randomized controlled trials, START, TEMPRANO and HPTN 052 show the
clinical benefit of early initiation of antiretroviral treatment (ART) in HIV-infected persons and in reducing HIV
transmission. The trials influenced the World Health Organization (WHO) decision to issue updated
recommendations to prescribe ART to all individuals living with HIV, irrespective of age and CD4 cell count.
Discussion: It is clear that the new 2015 WHO recommendations if followed, will change the face of the HIV
epidemic and probably curb its burden over time. Implementation however, requires that health systems, especially
those in low and middle-income settings, be ready to face this challenge on a large scale. HIV prevention and
treatment are easy in theory yet hard in practice. The new WHO guidelines for initiation of ART regardless of CD4
cell count will lead to upfront increases in the costs of healthcare delivery as the goal is to treat all those now
newly eligible for ART. Around 22 million people living with HIV qualify and will therefore require ART. Related
challenges immediately follow: firstly, that everyone must be tested for HIV; secondly, that anyone who has had an
HIV test should know their result and understand its significance; and, thirdly, that every person identified as
HIV-positive should receive and remain on ART. The emergence of HIV drug resistant strains when treatment is
started at higher CD4 cell count thresholds is a further concern as persons on HIV treatment for longer periods of
time are at increased risk of intermittent medication adherence.
Conclusions: The new WHO recommendations for ART are welcome, but lacking as they fail to consider
meaningful solutions to the challenges inherent to implementation. They fail to incorporate actual strategies on
how to disseminate and adopt these far-reaching guidelines, especially in sub-Saharan Africa, an area with weak
healthcare infrastructures. Well-designed, high-quality research is needed to assess the feasibility, safety,
acceptability, impact, and cost of innovations such as the universal voluntary testing and immediate treatment
approaches, and broad consultation must address community, human rights, ethical, and political concerns.
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Background
In 2013, the World Health Organization (WHO) recom-
mended that antiretroviral therapy (ART) should be
prescribed to individuals infected with human immuno-
deficiency virus (HIV) whose CD4+ T-cell (CD4) counts
were less than 500 cells per μL, to HIV-infected preg-
nant women, to HIV-discordant partners, to persons
with certain medical conditions such as active tubercu-
losis and active hepatitis B and to individuals with severe
or advanced HIV clinical disease [1]. The quality of
evidence for the 2013 recommendations varies from low
(pregnant women, tuberculosis and hepatitis B) to high
(serodiscordant couples) related to the methodological
quality of conducted studies in this field [2]. Although
the debate continues about the optimal timing of ART
initiation in the course of HIV infection, several lines of
evidence indicate that starting ART as soon as possible
in HIV patients is advantageous. In 2009, a mathematical
model using a hypothetical population and available data
and assumptions (including heterosexual mode of trans-
mission) relative to a South African setting suggested
that scaled-up universal voluntary HIV testing with
immediate ART, combined with existing prevention
approaches like circumcision, would have a major effect
on severe generalized HIV epidemics, leading to a near
stoppage of HIV transmission [2]. Variability in social
issues between HIV epidemics is an important consider-
ation. Indeed, any model should integrate characteristics
of the sexual partner network, voluntary HIV counseling
and testing uptake, linkage to care, ART coverage, and
consideration of key populations [3–5]. A more recent
mathematical model (also assuming heterosexual trans-
mission) addresses the feasibility of widespread ART
prescription within the context of a clinical trial con-
ducted in Zambia and South Africa and indicates that a
prevention package including home-based voluntary
testing and counseling, and ART for HIV positive indi-
viduals could reduce HIV incidence by more than 60 %
over 3 years [6]. It has also been demonstrated in
well-conducted, large observational studies that HIV in-
fection incidence at the community level can be reduced
by early ART initiation [7, 8].
Three recently published randomized controlled trials,
START [9], TEMPRANO [10] and HPTN 052 [11] have
shown promising, albeit modest benefit for HIV-infected
persons at an individual level, and for reducing HIV
transmission following early treatment initiation. All the
trials significantly informed the WHO in decision to
issue the updated recommendation in September 2015
that immediate ART be initiated in all individuals diag-
nosed with HIV, irrespective of age and CD4 cell count
[12]. The new 2015 guidelines also integrate for the first
time, the provision of pre-exposure prophylactic (PrEP)
interventions for all individuals at high risk of HIV in-
fection. The recommendation for PrEP is based on clin-
ical trial results confirming the effectiveness of tenofovir
for use as PrEP to prevent people from acquiring HIV in
a wide variety of settings and populations [13–15].
The Joint United Nations Program on HIV/AIDS
(UNAIDS) has an ambitious goal that by 2020, 90 % of
all people living with HIV should know their HIV status;
90 % of people diagnosed with HIV infection should re-
ceive sustained ART; and 90 % of all people receiving
ART should have ribonucleic acid HIV suppression [16].
It is clear that if widely and successfully carried out, the
new 2015 WHO recommendations will change the face
of the HIV epidemic and may significantly curb its bur-
den. However, successful adoption of the guidelines re-
quires that health systems, particularly those in low and
middle income settings, be prepared to face the chal-
lenges that implementation will bring. The aim of this
paper is to present challenges of the implementation of
the new WHO guidelines that is, initiating ART regard-
less of CD4 cell count.
Challenges of the implementation of the new
WHO guidelines
Challenges for health systems in Africa
Table 1 summarizes challenges in meeting the new
WHO guidelines. HIV prevention and treatment are
easy to delineate in theory, but hard to implement in
practice. The new WHO recommendations for initiation
of ART regardless of CD4 cell count will incur increased
costs for such treatment of all HIV-infected people [17].
Of the 37 million HIV-infected people across the globe,
70 % reside in sub-Saharan Africa, which is the most af-
fected region. Of all HIV-infected people across the
globe, only 15 million actually receive ART. Thus, we es-
timate that about 22 million (around 60 %) people living
with HIV/acquired immunodeficiency syndrome (AIDS)
will now be additional candidates for ART based on the
newest WHO guidelines, and that their ART treatment
should be initiated as soon as possible. Certain health
care facilities in sub-Saharan Africa which will be distri-
bution centers for ART have insufficient (or no) stock of
ART. The absence of ART drugs is a major “real life”
threat to the implementation of universal testing and
immediate treatment. In such a situation, how will
health systems in sub-Saharan Africa guarantee that
ART medication be available to patients when indicated,
and how will they realistically be able to meet the work-
load involved in adherence to the WHO recommenda-
tions and guidelines? Significant financial resources and
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logistical support are urgently needed to guarantee ad-
equate supplies of ART day-to-day and to ensure the
manpower for screening, counselling, and follow-up over
time. Health policy makers and funders should actively
engage in all aspects of relevant initiatives geared to fa-
cilitating the adoption practices that lead to compliance
with the 2015 WHO mandates.
Challenges for HIV testing
Barriers for HIV testing in Africa can include no propos-
ing for HIV testing during health consultations; thinking
not at risk for HIV infection; fear of being HIV positive;
fear of stigma if HIV positive; no available cure; fear of
no privacy and no confidentiality, no permission from
partner especially for women [18]. Strategies are needed
to properly diagnose all HIV-infected people, focusing
on those whose HIV status is presently unknown.
Worldwide, only half of the persons with HIV infection
are aware of their status [17] and in low-income and
middle-income countries only 20 % know about their
seropositive status [5]. Early diagnosis and timely access
to care can improve the clinical course of the disease
and potentially reduce transmission rates. The greatest
difficulty is to know how to ensure that everyone has ac-
cess to HIV testing in a weak healthcare system. If the
test is available, how to ensure that everyone who has
access to HIV testing be tested? How to get people to go
to HIV clinics for testing? On the other hand, what are
the ways and methods that can be used to reach all the
people by going to them for HIV testing? While system-
atic HIV testing can be used in primary health care set-
ting [19], another approach would be to conduct a
community-based integrated prevention campaign [20],
national HIV voluntary counseling and testing campaign
[21], or mobile HIV testing [22–26]. Throughout differ-
ent regions in Africa with different cultures, researches
are needed to identify specific determinants related to
non-acceptance of voluntary HIV counseling and testing
[27–30]. This will help understand why some people do
not accept HIV testing.
HIV can be diagnosed both in symptomatic and in
asymptomatic individuals. Among those who are asymp-
tomatic, HIV voluntary counseling and testing is the first
step to introducing people to effective HIV/AIDS care,
and is a focal point of HIV prevention in developing
countries [31–33]. The facts highlight several crucial
challenges: firstly, that everyone must be tested for HIV;
secondly, that anyone who has had HIV testing should
know their result and understand its significance; thirdly,
that a person identified as HIV-positive should receive
and remain on ART. Expanding universal HIV testing
will require innovative approaches such as home-based
HIV counseling and testing [34, 35]. There is recent evi-
dence from two randomized controlled trials that home-
based voluntary HIV counseling and testing increases
the overall rate of HIV testing and an individual’s knowledge
of their HIV status, when compared to health care facility-
based HIV interventions [36–38]. The generalizability
of findings from such randomized controlled trials to
“real world” settings remains undetermined.
Challenges for linkage to care and early/immediate
initiation of antiretroviral therapy
While definitions vary concerning linkage to care [39, 40],
the most important endpoint is now immediate initiation
of ART regarding new 2015 WHO guidelines [12]. Home-
based interventions are a necessary first step to introduce
increased ART coverage to eligible patients. The next
steps include the prescription of indicated medication,
and the long-term adherence to that treatment. Before
this, it is necessary that newly infected people link to
health facilities for ART initiation. A call center can be
used to increase linkage to care [39]. Two ongoing
Table 1 Challenges for the implementation of antiretroviral
therapy for all HIV-infected people regardless of CD4 cell count
in Africa
Challenges for health systems in Africa
• Lack of required financial resources for HIV programs
• Increase in healthcare workers’ workload without corresponding
increase in manpower
• Inadequate stocks of antiretroviral therapy
• Limited supportive health system infrastructures in resource limited
settings
Challenges for universal HIV testing
• Fear of being HIV positive, fear of stigma and discrimination during
home-based HIV testing
• Thoughts of not being at risk for HIV infection
• Fear of lack of privacy and confidentiality during home-based HIV
testing
• Need of spouses’ for HIV home testing
• Lack of proposition of HIV testing in some health facilities
• Lack of mobile HIV testing in some settings
Challenges for linkage to care and early/immediate initiation of
antiretroviral therapy
• Weak relation between mobile and home based HIV testing and
health facility based antiretroviral initiation
• True refusal and false acceptance of ART initiation after HIV positive
testing at home or by mobile units
• Absence of specific guidance on actual “real-life” implementation of
screening, diagnosis, and initiation of antiretroviral therapy in all
HIV-infected persons in resource-limited settings
Challenges for retention in care and adherence to antiretroviral treatment
• Absence of proven methods to ensure long time adherence to ART
and retention in care for all HIV-infected persons in resource limited
setting
• Weak early warning indicators for HIV drug resistance
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randomized trials conducted under real conditions to as-
sess the effectiveness at the community level of immedi-
ately initiating ART after home-based HIV counseling and
testing in South-Africa and Zambia are underway [41, 42].
Immediate initiation of ART will likely prove burdensome
in terms of both cost and manpower for health systems in
sub-Saharan Africa and for HIV-infected patients.
Some HIV-infected people encounter obstacles in
accessing necessary HIV/AIDS care once their home-
based diagnosis is made when they receive a referral to a
health facility for the purpose of ART initiation and
follow-up. A recent South African study indicated that
only 12 % of people receiving an HIV diagnosis through
home-based diagnostic testing were linked to HIV/AIDS
care, including ART [37]. Innovative approaches imple-
menting effective strategies for screening, testing, and
maintaining HIV-infected patients on ART are therefore
necessary to address such gaps in developing countries.
Identification and implementation of relevant initiatives
are also challenges in their own right and although they
may differ from country to country, represent an urgent
public health imperative. Mobile units for example, have
shown their positive performance in increasing HIV
screening, retention in HIV treatment, and adherence to
ART [22–26], one of such barriers is ART refusal, a
phenomenon in which HIV-infected individuals choose
not to start treatment upon learning their ART eligibility
[43]. As shown in a study, subjects which are tested in
an HIV clinic were more likely to link to care and thus
to initiate ART compared to subjects using HIV mobile
testing [23]. However, facility based HIV counseling and
testing, although important, is unlikely to be sufficient
to curb the HIV epidemic since many people in sub-
Saharan Africa do not have regular access to health care.
As concluded in a systematic review, scaling a combin-
ation of community HIV testing and counselling, mobile
testing and self-testing, with regard to the local epidemic
setting, is crucial to achieve high knowledge of HIV sta-
tus and linkage to HIV treatment and prevention in sub-
Saharan Africa [40]. The next logical step after testing
for HIV using that novel approach would be the pre-
scription of treatment via these mobile units or home-
based teams. Unfortunately these strategies have not
been rigorously assessed scientifically or validated in the
field. Targeted strategies will furthermore need to be im-
plemented to diagnose and treat currently underserved
and difficult-to-reach populations, such as men who
have sex with men, sex workers, injecting drug users,
and transgender individuals.
Challenges for retention in care and adherence to
antiretroviral treatment
The emergence of drug resistant HIV strains is a con-
cern in situations where ART is started early [43, 44], as
in treatment regimens where of ART is initiated irre-
spective of CD4 cell counts, since people will be on HIV
treatment for longer with increased potential for of sub-
optimal (intermittent) adherence. One hypothesis is that
some HIV-infected people with early/immediate ART
initiation, may feel well and perceive themselves as
“healthy” and consequently take ART intermittently, pla-
cing them at risk for the emergence of ART resistance
or become lost to follow-up. However, this should not
slow down the early/immediate ART initiation once the
HIV diagnosis is done since several studies reported that
ART initiation at high CD4 cell count was associated
with low HIV drug resistance [45, 46]. Long duration
randomized controlled trials are needed to confirm find-
ings of observational studies. Although the limited avail-
able data do not conclusively suggest an increased risk
of drug resistance with earlier HIV treatment, it remains
a concern and health care systems should consider mea-
sures to encourage long-term adherence. The immediate
initiation of ART itself along with better coverage of all
people living with HIV, might lead to a “normalization”
and greater acceptance of ART. This “normalization”
could reduce the stigmatization of people living with
HIV and contribute to improved treatment adherence
rates.
To measure the resistance to ART, the WHO recom-
mends that health systems use early warning indicators
for HIV drug resistance [47]. These indicators include
good ART prescribing practices, low rate of patients lost
to follow-up, high rate of patient retention on first line
ART; a good on-time drug pick-up, and continuous drug
supply. These indicators are part of the continuum of
HIV infection control (testing, linkage, retention, treat-
ment, and adherence) which are necessary to achieve the
UNAIDS 90-90-90 target [16]. Studies demonstrated
that in Africa some of these early warning indicators for
HIV drug resistance are very weak [48–52]. How can
these weak health systems fill out WHO and UNAIDS
goals?
Conclusions
The 2015 WHO recommendations regarding the broad
prescription of ART in all HIV-infected individuals have
a rational basis and are scientifically sound, yet, they are
also to a large extent challenging. Compliance with the
guidelines will lead to upfront increases in the costs of
healthcare delivery given the goal of treating all those
now newly eligible for ART, a number that approaches
22 million people living with HIV. Lacking is guidance
as to actual strategies on how to disseminate and imple-
ment the recommendations at the community level, es-
pecially in sub-Saharan Africa, a region with a heavy
burden of HIV and AIDS and weak health care systems.
High quality research to assess the feasibility, acceptability,
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impact, safety, and cost of innovations such as universal
voluntary testing and immediate treatment in real world
settings is crucial at this juncture in time, and broad col-
laborations are urgently needed to address community,
human rights, ethical, and political concerns. Discussion is
also needed on ART provision for HIV infected people
during epidemics of varying intensity. WHO has commit-
ted to promoting consultation among countries and stake-
holders about the pressing biomedical and political issues
of ART for HIV prevention regardless of CD4cell counts.
We fervently hope that the commitment will yield
tangible and practical guidance along with targeted
funding to help bring the recommended treatment to
those who need it most.
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